Viewpoint and CommentaryCommentaryGenotyping: One Piece of the Puzzle to Personalize Antiplatelet Therapy
Commentary
Under an Elsevier user license
open archive
Key Words
genotyping
antiplatelet therapy
CYP2C19*2
Abbreviations and Acronyms
ADP
adenosine diphosphate
CYP
hepatic cytochrome P450
HPR
high on-treatment platelet reactivity
HR
hazard ratio
SNP
single-nucleotide polymorphism
Cited by (0)
Dr. Gurbel has received research grants from AstraZeneca, Portola Pharmaceuticals, Pozen Inc., and Sanofi-Aventis, and is a consultant for and has received honoraria from AstraZeneca, Portola Pharmaceuticals, Pozen Inc., Sanofi-Aventis, Bayer AG, Eli Lilly and Company, Daiichi-Sankyo, and Schering-Plough. Dr. Kereiakes has received research grants from Daiichi-Sankyo, Abbott Vascular, Amylin Pharmaceuticals, and Boston Scientific; has received consulting fees from Eli Lilly and Company, Devax, Boston Scientific, Abbott Vascular, Medpace, and REVA Medical Inc.; and is on the Speakers Bureau of Eli Lilly and Company.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.